Eisai Aricept, Aciphex, Cerebyx, rasagiline, product and drug information


About Eisai
human health care Mission
Vision and Values
Community Involvement
Caring to Help Others Manual
Major Milestones
Parent Company
Oncology
Partnering with Eisai
Breast Cancer Support Organizations
Disease Information
Advanced Breast Cancer Disease Information
Breast Cancer Support Organizations
Cutaneous T-Cell Lymphoma Disease Information
Cutaneous T-Cell Lymphoma Support Organizations
AIDS (Acquired Immune Deficiency Syndrome)-Related Kaposi's Sarcoma Disease Information
Kaposi's Sarcoma Support Information
Corporate Responsibility
Industry Practices
Medical Education Grants (ME)
Eisai Medical Services
Eisai Assistance Programs
Manufacturing
Environment, Health and Safety
Our Products
ARICEPT^®
ACIPHEX^®
BANZEL^®
ZONEGRAN^®
FRAGMIN^®
Distributors
Pharmacy Trade Relations
Oncology Products
Aloxi^® (palonosetron hydrochloride)
DACOGEN^® (decitabine) for Injection
HALAVEN^® (eribulin mesylate) Injection
ONTAK® (denileukin diftitox)
Panretin® (alitretinoin) gel 0.1%
Research
Eisai's Oncology Clinical Trials
Investigator Initiated Studies (IIS)
Eisai's Global Pipeline
Eisai Careers
Career Opportunities
About Eisai Inc.
Benefits
Agency Portal
College/University
Summer MBA Program
Intern, Finance & Accounting
E-Verify
Press Room
Press Releases
Awards and Honors
Press Kits
Contacts
Investor Relations